Search
Back 

Organizational Structure

Organizational Structure

Overview of Committees

The Concept Prioritization Advisory Committee, Research Strategy Committee, various scientific committees, and administrative committees, as shown in the figure below, will carry out research planning and the implementation of NRG Oncology functions.

In addition to the three chairs, six NRG Oncology deputy group chairs will lead specific group functions

  • Research Strategy: Mitchell Machtay, MD
  • Protocol Prioritization and Conduct: J. Tate Thigpen, MD
  • Scientific Publications: Deborah Bruner, PhD
  • Membership: D. Lawrence Wickerham, MD
  • Research Integrity: Larry J. Copeland, MD
  • Communications: Thomas B. Julian, MD

NRG Oncology Foundation, Inc. Board of Directors

This board will be chaired by one of NRG Oncology’s group chairs and will consist of 17 members: the three group chairs, six appointments by the chairs, three representatives from the institutions, the contact PI for the NRG Oncology Statistical and Data Management Center (SDMC), a patient advocate, an outside financial expert, a Community Clinical Oncology Program (CCOP) representative, and an ad hoc member appointed by the group chairs. The board will ensure the appropriate allocation of NRG Oncology resources, allowing the group to fulfill its mission of improving the lives of adults with localized or locally advanced malignancies through the conduct of multi-institutional research trials. All other committees will be responsible for submitting or presenting their reports and recommendations to the board for review.

External Scientific Advisory Board (ESAB)

This group will consist of investigators experienced in the conduct of high-quality clinical and translational research to assess the group’s success in fulfilling its mission. They will not be current NRG members.  The ESAB will meet at least annually to review the group’s progress.  Members of the ESAB will be appointed by the group chairs and will report recommendations to them.

Overview of Committees

The Concept Prioritization Advisory Committee, Research Strategy Committee, various scientific committees, and administrative committees, as shown in the figure below, will carry out research planning and the implementation of NRG Oncology functions.

NRG Oncology Group Executive Committee

This committee will comprise the NRG Oncology group chairs, the deputy group chairs, the group statisticians, and the executive directors of the Operations Center, and will be chaired by the presiding group chair. It will meet regularly to ensure that the priorities set by the Foundation board are operationalized in the group’s research strategy and supported by appropriate Operations Center resources. This committee will be advisory to the group chairs and not a decision-making committee.

Disease Site Committees

The seven cancer disease site committees (brain tumor, head and neck cancer, lung cancer, breast cancer, gastrointestinal cancer, genitourinary cancer, and gynecologic cancer) will be the units within which most protocols will be developed and executed. The group chairs will appoint the leaders of these committees for 5-year terms, and for no more than two successive terms per individual. Chairs of these committees also will participate in the NCI disease site steering committees, each of which will be responsible for developing both long- and short-term strategic research plans for common and rare malignancies in their domain and for presenting these visions to NRG Oncology’s Research Strategy Committee.

Non-Disease Site Scientific Committees

In addition to the disease site committees, four other committees will conduct NRG Oncology trials as well as support research within the disease site committees: the Translational Science, Developmental Therapeutics (DT), Cancer Prevention and Control (CPC), and Patient-Centered Outcomes Research (PCOR) committees.

Scientific Core Committees

Seven scientific core committees will serve as shared resources of expertise and, in some cases, technology, enabling disease site and non-disease site scientific committee investigators to develop and execute high-quality research trials. The leaders and co-leaders of these committees will be appointed by the group chairs and will have membership chosen for expertise applicable to the overall priorities of NRG Oncology, as well as to each of its disease site committees. They include the Pathology Committee, Surgical Oncology Committee, Medical Oncology Committee, Radiation Oncology Committee, Patient Advocate Committee, Special Populations Committee, and Protocol Support Committee.

Research Strategy Committee

This scientific committee, led by the deputy group chair for research strategy, will be responsible for coordinating the scientific agenda for the group in accordance with its strategic themes, the group’s strengths, and the research needs of the overall NCTN. The RSC will focus on study development and will provide feedback and recommendations to the disease site and scientific core committees. This committee also will provide regular reports to the NRG Oncology Foundation board.

Concept Prioritization Advisory Committee (CPAC)

Chaired by the deputy group chair for protocol prioritization and conduct, this scientific committee will provide a rigorous and objective evaluation of the scientific merit and feasibility of NRG Oncology research concepts that have been vetted by the RSC, with final recommendations, including prioritization scores, sent to the group chairs for final approval. In addition, CPAC will be responsible for monitoring the progress of active studies, for the timeliness of results reporting in concert with the appropriate scientific committee, and for reporting these activities to the NRG Oncology Foundation board.

Publications Committee

Chaired by the deputy group chair for scientific publications, this body will develop and enforce the NRG Oncology publications policy, which governs issues including manuscript development and writing, authorship, peer review, timeliness monitoring, confidentiality matters, and other issues as required. This committee will review and facilitate proposed changes to policy or to general group publications operations procedures.

Membership Committee

Chaired by the deputy group chair for membership, this committee will be responsible for establishing the criteria for initial and ongoing institutional membership for submission to and final approval by the group chairs. This committee will also review and recommend new institutions for membership in NRG Oncology and recommend corrective actions as needed for existing members.

Communications Committee

Chaired by the deputy group chair for communications, this committee will be charged with developing an effective communications strategy for its members, the oncology community, and the general public. The committee will also be responsible for developing and updating an Internet strategy for the group.

Audit/Quality Control Committee

Chaired by the deputy group chair for research integrity, this committee will oversee the NCI-mandated on-site audit program, supervise the documentation of the accuracy of the data submitted to NRG Oncology, and verify investigator compliance with regulatory and group requirements for clinical trials. The deputy group chair for research integrity will serve as the NRG Oncology research misconduct officer.

Data Monitoring Committee

Governed by the NCI Data Monitoring Policy, the DMC will review the efficacy and morbidity data for each NRG Oncology clinical trial to ensure that decisions regarding continuation of these trials are both scientifically sound and ethically responsible. The DMC will make recommendations to the group chairs for a final decision. The DMC will be chaired by a non-NRG Oncology member with appropriate qualifications for this role.

 

Copyright 2017 by NRG Oncology